Literature DB >> 2991571

Potent neutralizing activity associated with anti-glycoprotein D specificity among monoclonal antibodies selected for binding to herpes simplex virions.

M F Para, M L Parish, A G Noble, P G Spear.   

Abstract

Thirty-three monoclonal antibodies were selected for ability to bind to purified virions of herpes simplex virus and were shown by immunoprecipitation to react with one or another of the envelope glycoproteins. Only six of these antibodies exhibited potent neutralizing activity, and all six were specific for glycoprotein D. Two other anti-glycoprotein D antibodies and 25 antibodies specific for four other viral glycoproteins had much less potent, if any, neutralizing activity.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2991571      PMCID: PMC254957     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  38 in total

1.  Localization and synthesis of an antigenic determinant of herpes simplex virus glycoprotein D that stimulates the production of neutralizing antibody.

Authors:  G H Cohen; B Dietzschold; M Ponce de Leon; D Long; E Golub; A Varrichio; L Pereira; R J Eisenberg
Journal:  J Virol       Date:  1984-01       Impact factor: 5.103

2.  Purification of glycoprotein gD of herpes simplex virus types 1 and 2 by use of monoclonal antibody.

Authors:  R J Eisenberg; M Ponce de Leon; L Pereira; D Long; G H Cohen
Journal:  J Virol       Date:  1982-03       Impact factor: 5.103

3.  Anti-gD monoclonal antibodies inhibit cell fusion induced by herpes simplex virus type 1.

Authors:  A G Noble; G T Lee; R Sprague; M L Parish; P G Spear
Journal:  Virology       Date:  1983-08       Impact factor: 3.616

4.  Use of monoclonal antibodies against two 75,000-molecular-weight glycoproteins specified by herpes simplex virus type 2 in glycoprotein identification and gene mapping.

Authors:  M F Para; K M Zezulak; A J Conley; M Weinberger; K Snitzer; P G Spear
Journal:  J Virol       Date:  1983-03       Impact factor: 5.103

5.  Glycoproteins of herpes simplex virus type 2 as defined by monoclonal antibodies.

Authors:  N Balachandran; D Harnish; W E Rawls; S Bacchetti
Journal:  J Virol       Date:  1982-10       Impact factor: 5.103

6.  Use of monoclonal antibodies for analysis of antibody-dependent immunity to ocular herpes simplex virus type 1 infection.

Authors:  J T Rector; R N Lausch; J E Oakes
Journal:  Infect Immun       Date:  1982-10       Impact factor: 3.441

7.  Glycoprotein gE of herpes simplex virus type 1: effects of anti-gE on virion infectivity and on virus-induced fc-binding receptors.

Authors:  M F Para; R B Baucke; P G Spear
Journal:  J Virol       Date:  1982-01       Impact factor: 5.103

8.  Characterization of a herpes simplex virus type 2 75,000-molecular-weight glycoprotein antigenically related to herpes simplex virus type 1 glycoprotein C.

Authors:  K M Zezulak; P G Spear
Journal:  J Virol       Date:  1983-09       Impact factor: 5.103

9.  Identification and preliminary mapping with monoclonal antibodies of a herpes simplex virus 2 glycoprotein lacking a known type 1 counterpart.

Authors:  B Roizman; B Norrild; C Chan; L Pereira
Journal:  Virology       Date:  1984-02       Impact factor: 3.616

10.  Antigenic variants of herpes simplex virus selected with glycoprotein-specific monoclonal antibodies.

Authors:  T C Holland; S D Marlin; M Levine; J Glorioso
Journal:  J Virol       Date:  1983-02       Impact factor: 5.103

View more
  54 in total

1.  Activation of cJUN N-terminal kinase by herpes simplex virus type 1 enhances viral replication.

Authors:  T I McLean; S L Bachenheimer
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

2.  Redistribution of cellular and herpes simplex virus proteins from the trans-golgi network to cell junctions without enveloped capsids.

Authors:  Todd W Wisner; David C Johnson
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

3.  Residues within the C-terminal arm of the herpes simplex virus 1 glycoprotein B ectodomain contribute to its refolding during the fusion step of virus entry.

Authors:  Sarah A Connolly; Richard Longnecker
Journal:  J Virol       Date:  2012-04-04       Impact factor: 5.103

4.  Glycoprotein B of herpes simplex virus 2 has more than one intracellular conformation and is altered by low pH.

Authors:  Martin I Muggeridge
Journal:  J Virol       Date:  2012-04-18       Impact factor: 5.103

5.  Evaluation of pseudorabies virus glycoprotein gp50 as a vaccine for Aujeszky's disease in mice and swine: expression by vaccinia virus and Chinese hamster ovary cells.

Authors:  C C Marchioli; R J Yancey; E A Petrovskis; J G Timmins; L E Post
Journal:  J Virol       Date:  1987-12       Impact factor: 5.103

6.  Identification of a site on herpes simplex virus type 1 glycoprotein D that is essential for infectivity.

Authors:  M I Muggeridge; W C Wilcox; G H Cohen; R J Eisenberg
Journal:  J Virol       Date:  1990-08       Impact factor: 5.103

7.  Antigenic and mutational analyses of herpes simplex virus glycoprotein B reveal four functional regions.

Authors:  Florent C Bender; Minu Samanta; Ekaterina E Heldwein; Manuel Ponce de Leon; Elina Bilman; Huan Lou; J Charles Whitbeck; Roselyn J Eisenberg; Gary H Cohen
Journal:  J Virol       Date:  2007-01-31       Impact factor: 5.103

8.  Random linker-insertion mutagenesis to identify functional domains of herpes simplex virus type 1 glycoprotein B.

Authors:  Erick Lin; Patricia G Spear
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-31       Impact factor: 11.205

9.  HveA (herpesvirus entry mediator A), a coreceptor for herpes simplex virus entry, also participates in virus-induced cell fusion.

Authors:  T Terry-Allison; R I Montgomery; J C Whitbeck; R Xu; G H Cohen; R J Eisenberg; P G Spear
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

10.  Intra-nuclear localization of two envelope proteins, gB and gD, of herpes simplex virus.

Authors:  L M Stannard; S Himmelhoch; S Wynchank
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.